THE WELCH COMPANY
440 Davis Court #1602
San Francisco, CA 94111-2496
415 781 5700
rodwelch@pacbell.net
S U M M A R Y
DIARY: August 28, 2008 08:00 AM Thursday;
Rod Welch
Millie 2nd treatment 7th cycle cetuximab Carboplatin 4th relapse IBC.
1...Summary/Objective
...Taxotere Capecitabine 2nd Relapse IBC Treatment After Mastectomy
...Cetuxiab Alone Clinical Study
...Cetuxiab 81 and Carboplatin 14 Treatments Clinical Study 2nd Arm
2...Schedule Weekly Treatments Continue on Thursdays
3...Labs Blood Test
4...NEUTS 3.09 Increase 2nd Week Chemotherapy Approved
5...Chemotherapy Carboplatin Approved Blood Counts Rise Significantly
6...Blood Counts Rise Significantly Chemotherapy Carboplatin Approved
7...Case Study Neutropenia 26 Treatments Neupogen Missed 4 Chemotherapy
8...Neupogen 26 Treatments Neutropenia Missed Carboplatin 4 Treatments
9...Neupogen Side Effects Case Study Indicates Good Tolerance
10...Side Effects Neupogen Treatments Continue Mild Tolerance Acceptable
11...Carboplatin Chemotherapy Orders
..............
Click here to comment!
CONTACTS
SUBJECTS
Cetuximab Carboplatin Clinical Study 2nd Arm 7th Cycle 1st Treatment
1003 -
1003 - ..
1004 - Summary/Objective
1005 -
100501 - Follow up ref SDS F3 0000. ref SDS F1 0000.
100502 -
100503 -
100504 -
100505 -
100506 -
100507 -
100508 -
100510 - ..
1006 -
1007 -
1008 - Progress
1009 -
100901 - Background on Millie's treatment in the clinical study is reported on
100902 - 080508. ref SDS 97 TZ8I
100904 - ..
100905 - Taxotere Capecitabine 2nd Relapse IBC Treatment After Mastectomy
100906 -
100907 - Follow up ref SDS F3 X33O, ref SDS F1 X33O.
100908 -
100909 - Millie had left mastectomy on 051021. Biopsy at that time reported
100910 - no findings of cancer. Approximately 8 months later on 060707 the
100911 - doctor diagnosed IBC relapse and prescribed treatment with
100912 - capecitabine and Taxotere, which had been effective in 2005
100913 - completely eliminating signs of IBC disease. ref SDS 5 PF3O
100914 -
100915 - 1. Cycle 09 and 01 ................... 060721, ref SDS 6 407N
100916 - 2. Cycle 10 and 02 ................... 060814, ref SDS 8 LY6O
100917 - 3. Cycle 11 and 03 ................... 060908, ref SDS 8 407N
100918 - 4. Cycle 12 and 04 ................... 060929, ref SDS 8 407N
100919 - 5. Cycle 13 and 05 ................... 061020, ref SDS 9 407N
100920 - 6. Cycle 14 and 06 ................... 061110, ref SDS 10 407N
100921 - 7. Cycle 15 and 07 ................... 061201, ref SDS 11 407N
100923 - ..
100924 - Cetuxiab Alone Clinical Study
100925 -
100926 - Follow up ref SDS F3 356I, ref SDS F1 356I.
100927 -
100928 - After 7 cycles of treatment in 2006, the doctor diagnosed IBC
100929 - disease was progressing, and so made referral to UCSF for referral
100930 - in clinical study of Cetuximab and Carboplatin. Millie was
100931 - randominzed for treatment with Cetuximab alone, and began weekly
100932 - treatments at UCSF on 080201.
100934 - ..
100935 - Total Cetuximab
100936 - 8. Cycle 01 and 08 and 01 01.......... 070201, ref SDS 13 SG8I
100937 - 9. Cycle 01 and 08 and 02 02.......... 070208, ref SDS 14 SG8I
100938 - 10. Cycle 01 and 08 and 03 03.......... 070215, ref SDS 15 SG8I
100939 - 11. Cycle 01 and 08 and 04 04.......... 070222, ref SDS 16 SG8I
100940 - 12. Cycle 02 and 09 and 01 05.......... 070301, ref SDS 17 SG8I
100941 - 13. Cycle 02 and 09 and 02 06.......... 070308, ref SDS 19 7T3H
100942 - 14. Cycle 02 and 09 and 03 07.......... 070315, ref SDS 20 7T3H
100943 - 15. Cycle 02 and 09 and 04 08.......... 070322, ref SDS 21 7T3H
100944 - 16. Cycle 03 and 10 and 01 09.......... 070329, ref SDS 22 7T3H
100945 - 17. Cycle 03 and 10 and 02 10.......... 070405, ref SDS 23 7T3H
100946 - 18. Cycle 03 and 10 and 03 11.......... 070412, ref SDS 24 7T3H
100947 - 19. Cycle 03 and 10 and 04 12.......... 070419, ref SDS 25 7T3H
100948 - 20. Cycle 04 and 11 and 01 13.......... 070426, ref SDS 26 7T3H
100949 - 21. Cycle 04 and 11 and 02 14.......... 070503, ref SDS 27 7T3H
100950 - 22. Cycle 04 and 11 and 03 15.......... 070510, ref SDS 28 7T3H
100951 - 23. Cycle 04 and 11 and 04 16.......... 070517, ref SDS 29 7T3H
100952 - 24. Cycle 05 and 12 and 01 17.......... 070524, ref SDS 30 7T3H
100953 - 25. Cycle 05 and 12 and 02 18.......... 070531, ref SDS 31 7T3H
100954 - 26. Cycle 05 and 12 and 03 19.......... 070607, ref SDS 32 7T3H
100955 - 27. Cycle 05 and 12 and 04 20.......... 070614, ref SDS 33 0001
100956 - 28. Cycle 06 and 13 and 01 21.......... 070621, ref SDS 34 0001
100957 - 29. Cycle 06 and 13 and 02 22.......... 070628, ref SDS 35 0001
100958 - 30. Cycle 06 and 13 and 03 23.......... 070705, ref SDS 36 0001
100959 - 31. Cycle 06 and 13 and 04 24.......... 070712, ref SDS 36 0001
100960 - 32. Cycle 07 and 14 and 01 25.......... 070719, ref SDS 37 0001
100961 - 33. Cycle 07 and 14 and 02 26.......... 070726, ref SDS 35 0001
100962 - 34. Cycle 07 and 14 and 03 27.......... 070802, ref SDS 36 0001
100963 - 35. Cycle 07 and 14 and 04 28.......... 070809, ref SDS 38 0001
100964 - 36. Cycle 08 and 15 and 01 29.......... 070816, ref SDS 39 0001
100965 - 37. Cycle 08 and 15 and 02 30.......... 070823, ref SDS 40 0001
100966 - 38. Cycle 08 and 15 and 03 31.......... 070830, ref SDS 40 0001
100967 - 39. Cycle 08 and 15 and 04 32.......... 070906, ref SDS 41 0001
100968 - 40. Cycle 09 and 16 and 01 33.......... 070920, ref SDS 42 0001
100969 - 41. Cycle 09 and 16 and 02 34.......... 070927, ref SDS 43 0001
100970 - 42. Cycle 09 and 16 and 03 35.......... 071004, ref SDS 44 0001
100971 - 43. Cycle 09 and 16 and 04 36.......... 071011, ref SDS 45 0001
100972 - 44. Cycle 10 and 17 and 01 37.......... 071018, ref SDS 46 0001
100973 - 45. Cycle 10 and 17 and 02 38.......... 071025, ref SDS 47 0001
100974 - 46. Cycle 10 and 17 and 03 39.......... 071101, ref SDS 33 0001
100975 - 47. Cycle 10 and 17 and 04 40.......... 071108, ref SDS 48 0001
100976 - 48. Cycle 11 and 18 and 01 41.......... 071115, ref SDS 49 0001
100977 - 49. Cycle 11 and 18 and 02 42.......... 071122, ref SDS 35 0001
100978 - 50. Cycle 11 and 18 and 03 43.......... 071129, ref SDS 52 0001
100979 - 51. Cycle 11 and 18 and 04 44.......... 071206, ref SDS 53 0001
100980 - 52. Cycle 12 and 19 and 01 45.......... 071213, ref SDS 56 0001
100981 - 53. Cycle 12 and 19 and 02 46.......... 071220, ref SDS 59 0001
100982 - 54. Cycle 12 and 19 and 03 47.......... 071227, ref SDS 60 0001
100983 - 55. Cycle 12 and 19 and 04 48.......... 080103, ref SDS 61 0001
100984 - 56. Cycle 13 and 20 and 01 49.......... 080110, ref SDS 64 0001
100985 - 57. Cycle 13 and 20 and 02 50.......... 080117, ref SDS 65 0001
100986 - 58. Cycle 13 and 20 and 03 51.......... 080124, ref SDS 66 0001
100987 - 59. Cycle 13 and 20 and 04 52.......... 080131, ref SDS 68 0001
100988 - 60. Cycle 14 and 21 and 01 53.......... 080207, ref SDS 72 0001
100989 - 61. Cycle 14 and 21 and 02 54.......... 080214, ref SDS 73 0001
100990 - 62. Cycle 14 and 21 and 03 55.......... 080221, ref SDS 36 0001
100991 - 63. Cycle 14 and 21 and 04 56.......... 080228, ref SDS 78 0001
100992 - 64. Cycle 15 and 22 and 01 57 01 00... 080306, ref SDS 81 TZ8I
100994 - ..
100995 - Cetuxiab 81 and Carboplatin 14 Treatments Clinical Study 2nd Arm
100996 -
100997 - Follow up ref SDS F3 5B6J, ref SDS F1 5B6J.
100998 -
100999 - On 080207 doctor reports IBC may be spreading. ref SDS 71 GH5H
101000 - Follow up examination on 080219 Doctor Rugo diagnosed progression of
101001 - disease. ref SDS 91 3J4I Photographs show spread of IBC rash, UCSF
101002 - prescribed treatment under the 2nd Arm of the study so that Millie
101003 - now gets weekly treatment with cetuximab and with Carboplatin 3
101004 - weeks of each 4 week cycle.
101005 -
101006 - 2nd
101007 - Arm Cetuximab Carboplatin
101008 - 65. Cycle 01 15 and 22 and 02 58 02 01... 080313, ref SDS 82 TZ8I
101009 - 66. Cycle 01 15 and 22 and 03 59 03 01... 080320, ref SDS 83 TZ8I
101010 - 67. Cycle 01 15 and 22 and 04 60 04 01... 080327, ref SDS 84 TZ8I
101011 - 68. Cycle 02 16 and 23 and 01 61 05 02... 080403, ref SDS 85 TZ8I
101012 - 69. Cycle 02 16 and 23 and 02 62 06 03... 080410, ref SDS 88 TZ8I
101013 - 70. Cycle 02 16 and 23 and 03 63 07 03... 080417, ref SDS 90 TZ8I
101014 - 71. Cycle 02 16 and 23 and 04 64 08 03... 080424, ref SDS 92 TZ8I
101015 - 72. Cycle 03 17 and 24 and 01 65 09 04... 080501, ref SDS 95 5B6J
101016 - 73. Cycle 03 17 and 24 and 02 66 10 05... 080508, ref SDS 97 5B6J
101017 - 74. Cycle 03 17 and 24 and 03 67 11 05... 080515, ref SDS 98 5B6J
101018 - 75. Cycle 03 17 and 24 and 04 68 12 05... 080522, ref SDS 99 5B6J
101019 - 76. Cycle 04 18 and 25 and 01 69 13 06... 080529, ref SDS A2 5B6J
101020 - 77. Cycle 04 18 and 25 and 02 70 14 07... 080605, ref SDS A3 5B6J
101021 - 78. Cycle 04 18 and 25 and 03 71 15 08... 080612, ref SDS A6 5B6J
101022 - 79. Cycle 04 18 and 25 and 04 72 16 08... 080619, ref SDS A9 5B6J
101023 - 80. Cycle 05 19 and 26 and 01 73 17 09... 080626, ref SDS B4 5B6J
101024 - 81. Cycle 05 19 and 26 and 02 74 18 10... 080703, ref SDS B9 5B6J
101025 - 82. Cycle 05 19 and 26 and 03 75 19 11... 080710, ref SDS C2 5B6J
101026 - 83. Cycle 05 19 and 26 and 04 76 20 11... 080717, ref SDS C8 5B6J
101027 - 84. Cycle 06 20 and 27 and 01 77 21 12... 080724, ref SDS D5 5B6J
101028 - 85. Cycle 06 20 and 27 and 02 78 22 13... 080731, ref SDS D9 5B6J
101029 - 86. Cycle 06 20 and 27 and 03 79 23 14... 080807, ref SDS E5 5B6J
101030 - 87. Cycle 06 20 and 27 and 04 80 24 14... 080814, ref SDS F1 5B6J
101031 - 88. Cycle 07 21 and 28 and 01 81 25 14... 080821, ref SDS F3 5B6J
101032 - 89. Cycle 07 21 and 28 and 02 82 26 15... 080828, ref SDS 0 5B6J
101034 - ..
101035 - Today is the 2nd treatment of the 7th cycle with cetuximab and
101036 - Carboplatin together. This is the 26th treatment overall with
101037 - cetuximab on the 2nd arm of the clinical study, but is only the 15th
101038 - treatment with Carboplatin due to low blood counts that caused Millie
101039 - to miss the first treatment of the cycle last week. ref SDS F3 V94O
101040 -
101041 -
101042 -
101043 -
101044 -
1011 -
SUBJECTS
Default Null Subject Account for Blank Record
1703 -
170401 - ..
170402 - Schedule Weekly Treatments Continue on Thursdays
170403 -
170404 - Follow up ref SDS E5 1K7H, ref SDS D5 1K7H.
170405 -
170406 - The current schedule is listed on 080724. ref SDS D5 1K7H
170407 -
170408 - We need Millie's schedule for October.
170409 -
170410 -
170411 -
170412 -
170413 -
170414 -
1705 -
SUBJECTS
Blood Tests Labs Infusion Clinic Evaluate Safe Chemotherapy 1st Trea
2503 -
2504 - 0750
250501 - ..
250502 - Labs Blood Test
250503 -
250504 - Follow up ref SDS F3 FW5N, ref SDS F1 FW5N.
250505 -
250506 - Adding Carboplatin to the treatment protocol now requires weekly blood
250507 - tests to determine if the immune system is strong enough for safe
250508 - chemotherapy treatment, reported on 070201, ref SDS 13 XR40, and
250509 - citing the clinical study protocol received from UCSF on 070116.
250510 - ref SDS 12 5U7Z
250512 - ..
250513 - The doctor's order for lab work was ready in the Infusion Clinic
250514 - today, implementing Millie's notice to the medical team yesterday on
250515 - 080827. ref SDS F6 P98Y
250516 -
250517 -
250518 -
250520 - ..
2506 -
2507 -
2508 - 1022
2509 -
250901 - During treatment, Catherine submitted results of the test for the 2nd
250902 - treatment of the 7th cycle. Scope is reduced from starting cycle 7 on
250903 - 080821, ref SDS F3 075H, and is the same for the 4th treatment of the
250904 - 6th cycle. ref SDS F1 075H
250905 -
250920 - ..
250921 - Log#: 080828 08:15
250922 - <----------------------- U C S F -----------------------> <------------- Kaiser -------------->
250923 - Type Results Units Normal ACRO Type Units Normal
250924 - ..
250925 - CBC with DIFF & PLT CT CBCD
250926 - ..
250927 - WBC COUNT 5.5 x10E9/L 3.4 - 10 WBC WBC x10-3 K/uL 3.4 - 10.0
250928 - RBC COUNT L 3.94 x10E12/L 4 - 5.2 RBC RBC x10-6 M/uL 3.60 - 5.70
250929 - HEMOGLOBIN 13.3 g/dL 12 - 15.5 HGB Hemoglobin g/dL 11.5 - 15.0
250930 - HEMATOCRIT 39.3 PERCENT 36 - 46 HCT Hematocrit % 34.0 - 46.0
250931 - MCV 100 fL 80 - 100 MCV MCV fL 80.0 - 100.0
250932 - MCH 33.7 pg 26 - 34 MCH
250933 - MCHC 33.8 g/dL 31 - 36 MCHC
250934 - PLATELETS 197 x10E9/L 140 - 450 PLT Plt x10-3 K/uL 140 - 400
250935 -
250936 - Performed at Mt Zion Clinic Lab, 1600 Divisadero, San
250937 - Francisco, CA 94115
250938 - ..
250939 - (NEUTS x 1000 = ANC for Kaiser)
250940 - NEUTS 3.09 x10E9/L 1.8 - 6.8 N-A ANC 1500
250941 - Neutrophils Not Reported Neutrophils % 50 - 70
250943 - ..
250944 - LYMPHS 1.70 x10E9/L 0.9 - 2.9 L-A Lymphocytes % 20 - 50
250945 - MONOS 0.32 x10E9/L 0.2 - 0.8 M-A Monocyte % 0 - 11
250946 - EOS 0.21 x10E9/L 0 - 0.4 E-A Esoinophils % 1 - 5
250947 - BASOS 0.05 x10E9/L 0 - 0.1 B-A Basophil % 0 - 2
250948 - LUC/ATYP LYMPHS 0.16 x10E9/L 0.0 - 0.2 LALA
250950 - ..
250951 - <----------------------- U C S F -----------------------> <------------- Kaiser -------------->
250952 - Type Results Units Normal ACRO Type Units Normal
250953 - ELECTROLYTE PANEL LYTE
250954 - ..
250955 - MAGNESIUM 2.0 mg/dL 1.8 - 2.3 MG Magnesium mg/dL 1.6 - 2.3
250957 - ..
250958 - CREAT with eGFR
250959 - CREATININE 0.55 mg/dL 0.42 - 1.06 CR Creatinine mg/dL 0.6 - 1.2
250960 -
250961 - Note: Creatinine assay changed to IDMS standardization on
250962 - February 4, 2008 causing decrease in results of approximately
250963 - 0.09 mg/dL
250965 - ..
250966 - eGFR if Caucasian >60 mL/min GFRC
250967 - eGFR if African Amer >60 mL/min GFRA
250968 -
250969 - eGFR corrected for 1.73 sq meters of body surface area
250970 - Note: eGFR is only an estimation. Please see online Lab Manual
250971 - for potential limitations.
250972 - Performed at Mt Zion Clin Lab, 1600 Divisadero, San Francisco,
250973 - CA 94115
250975 - ..
250976 - CA 15-3 96 reported by Catherine today for the blood test last week on
250977 - 080821. ref SDS F3 A16M
250978 -
250979 -
250980 -
250981 -
250982 -
2510 -
SUBJECTS
Absolute Neutrophils Count ANC 6850 Above 1500 NEUTS 6.85 Above 1.5
3403 -
340401 - ..
340402 - NEUTS 3.09 Increase 2nd Week Chemotherapy Approved
340403 - Chemotherapy Carboplatin Approved Blood Counts Rise Significantly
340404 - Blood Counts Rise Significantly Chemotherapy Carboplatin Approved
340405 -
340406 - Follow up ref SDS F3 PU6K, ref SDS F1 PU6K.
340407 -
340408 - Blood counts increased this week, shown by the Lab report today with
340409 - NEUTS 3.09, ref SDS 0 QY6H, compared with NEUTS 0.99 last week on
340410 - 080821, ref SDS F3 QY6H This well above UCSF standard of 1.5 for
340411 - Millie to safely get chemotherapy treatment. The doctor ordered
340412 - Carboplatin chemotherapy withheld last week on 080821, ref SDS F2
340413 - RV8O, and approved adding treatment with Neupogen oin 080822 and the
340414 - next day on Saturday, 080823, in order to increase blood counts enough
340415 - for safe chemotherapy treatment today, as reported in the record
340416 - meeting with the medical team in the Breast Care Clinic on the 2nd
340417 - floor. ref SDS F2 RV93
340419 - ..
340420 - Increase in blood counts today following big decline last week
340421 - demonstrates a roller coaster above and below specified target from
340422 - week to week, even while getting a steady dose of Neupogen in recent
340423 - months.
340425 - ..
340426 - Case study on 060809 shows Millie has often received chemotherapy when
340427 - blood counts are below the standard for safe treatments, and on some
340428 - occassions has received Neupogen to increase blood counts. ref SDS 7
340429 - HV45
340431 - ..
340432 - Big rise in blood counts NEUTS today, could justify getting only 1
340433 - Neupogen treatment this week, rather than 2. On the other hand,
340434 - importance of maintaining steady level of chemotherapy treatment for
340435 - cancer, indicates that risking NEUTS rising more than needed is a
340436 - smaller risk to health than skipping Neupogen that causes missed
340437 - cancer treatment.
340438 -
340439 -
340440 -
3405 -
SUBJECTS
Default Null Subject Account for Blank Record
3503 -
350401 - ..
350402 - Case Study Neutropenia 26 Treatments Neupogen Missed 4 Chemotherapy
350403 - Neupogen 26 Treatments Neutropenia Missed Carboplatin 4 Treatments
350404 -
350405 - Follow up ref SDS F3 EP7N.
350406 -
350407 - Millie has received 26 Neupogen treatments, and missed 4 chemotherapy
350408 - treatments due to rising neutropenia, and so has received only 15 of
350409 - 19 total treatments prescribed with Carboplatin, since starting the
350410 - 2nd arm of the clinical study on 080306...
350412 - ..
350413 - Neupogen Carboplatin
350414 - Date NEUTS Cur Totl Cycl Trm Rcvd Missed
350415 -
350416 - 080828 3.09 2 26 7 2 15.......... ref SDS 0 QY6H
350417 - 080821 0.99 2 24 7 1 14 4... ref SDS F3 QY6H
350418 - 080814 1.37 0 22 6 4 14.......... ref SDS F1 QY6H
350419 - 080807 2.41 2 22 6 3 14.......... ref SDS E5 QY6H
350420 - 080731 1.92 2 20 6 2 13.......... ref SDS D9 QY6H
350421 - 080724 2.32 2 18 6 1 12.......... ref SDS D5 QY6H
350422 - 080717 2.47 1 16 5 4 11.......... ref SDS C8 QY6H
350424 - ..
350425 - On 080718 2 Neupogen treatments were cancelled at Kaiser,
350426 - ref SDS C9 9W9I, because the day before at UCSF on 080717
350427 - NUETS were high, and there was no Carboplatin chemotherapy
350428 - treatment given for the 4th week in the cycle on 080717.
350430 - ..
350431 - On 080719 the day after CT testing, Millie went to Kaiser
350432 - and received 1 Neupogen treatment as a precaution ordered
350433 - by Kaiser after bleeding trauma during failed CT test using
350434 - the Power Port the day before on 080718. ref SDS D0 SR37
350436 - ..
350437 - Neupogen Carboplatin
350438 - Date NEUTS Cur Totl Cycl Trm Rcvd Missed
350439 -
350440 - 080710 5.12 2 15 5 3 11......... ref SDS C2 QY6H
350441 - 080703 2.90 2 13 5 2 10......... ref SDS B9 QY6H
350442 - 080626 1.80 2 11 5 1 09......... ref SDS B4 QY6H
350443 - 080619 0.74 1 9 4 4 08......... ref SDS A9 QY6H
350444 - 080612 3.77 2 8 4 3 08......... ref SDS A6 QY6H
350446 - ..
350447 - On 080609 Kaiser orders 2 Neupogen treatments per week in
350448 - Infusion Clinic, ref SDS A5 IL6I, for UCSF prescription in
350449 - Chemo Orders on 080529, ref SDS A5 L16I, which were
350450 - received on 080605. ref SDS A3 JN38
350452 - ..
350453 - Neupogen Carboplatin
350454 - Date NEUTS Cur Totl Cycl Trm Rcvd Missed
350455 -
350456 - 080605 1.55 2 6 4 2 07......... ref SDS A3 QY6H
350457 - 080529 2.26 1 4 4 1 06......... ref SDS A2 QY6H
350458 - 080522 0.96 0 3 4 05......... ref SDS 99 QY6H
350459 - 080515 1.21 0 3 3 05 3.. ref SDS 98 QY6H
350460 - 080508 5.41 1 3 3 2 05......... ref SDS 97 QY6H
350461 - 080501 1.34 1 2 3 1 04......... ref SDS 95 QY6H
350462 - 080424 1.34 0 2 4 03......... ref SDS 92 QY6H
350463 - 080417 0.95 0 2 3 03 2.. ref SDS 90 QY6H
350464 - 080410 6.85 0 2 2 03......... ref SDS 88 QY6H
350465 - 080403 1.34 1 1 2 1 02......... ref SDS 85 QY6H
350466 - 080327 2.30 0 1 4 01......... ref SDS 84 QY6H
350467 - 080320 1.28 0 1 3 01 1.. ref SDS 83 QY6H
350468 - 080313 2.05 0 1 2 01......... ref SDS 82 QY6H
350469 - 080306 1.75 0 1 1 00......... ref SDS 81 QY6H
350470 -
350471 -
350472 -
3505 -
SUBJECTS
Default Null Subject Account for Blank Record
3603 -
360401 - ..
360402 - Neupogen Side Effects Case Study Indicates Good Tolerance
360403 - Side Effects Neupogen Treatments Continue Mild Tolerance Acceptable
360404 -
360405 - Follow up ref SDS F3 SB8I, ref SDS F1 SB8I.
360406 -
360407 - Side effects of Neupogen may be lessening, reported on...
360408 -
360409 - 080825................, ref SDS F4 9W9I
360410 - 080810................, ref SDS E9 9W9I
360411 - 080803................, ref SDS E0 9W9I
360412 - 080726................, ref SDS D7 9W9I
360413 - 080721................, ref SDS D2 9W9I
360414 - 080713................, ref SDS C5 RM94
360415 - 080629................, ref SDS B8 6Q5J
360416 - 080628................, ref SDS B6 6Q5J
360417 -
360418 - ...suggesting increased ability to tolerate 2 Neupogen treatments per
360419 - week.
360420 -
360421 -
360422 -
360423 -
3605 -
SUBJECTS
Default Null Subject Account for Blank Record
3703 -
370401 - ..
370402 - Carboplatin Chemotherapy Orders
370403 -
370404 - Follow up ref SDS F3 N54I, ref SDS D5 N54I.
370405 -
370406 - Chemotherapy Order for Carboplatin was submitted today, because
370407 - Millie's blood counts were high enough for safe treatment, per above.
370408 - ref SDS 0 PU6K
370410 - ..
370411 - The order was submitted by Jill, per Millie's letter to the medical
370412 - team yesterday on 080827, ref SDS F6 KU5J, is reported in the record
370413 - last week on 080821 starting cycle 7 in order to maintain order in the
370414 - record. ref SDS F3 N54I
370415 -
370416 -
370417 -
370418 -
370419 -
370420 -
370421 -
3705 -